Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece
Nikos Maniadakis (),
Mattias Ekman (),
Vasiliki Papagiannopoulou () and
The European Journal of Health Economics, 2011, vol. 12, issue 3, pages 253-261
Keywords: Hypertension; Angiotensin-II inhibitors; Irbesartan; Economic; Cost; Effectiveness; D61; I19; C44; C02 (search for similar items in EconPapers)
References: View references in EconPapers View complete reference list from CitEc
Citations Track citations by RSS feed
Downloads: (external link)
Access to full text is restricted to subscribers.
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: http://EconPapers.repec.org/RePEc:spr:eujhec:v:12:y:2011:i:3:p:253-261
Ordering information: This journal article can be ordered from
Access Statistics for this article
The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg
More articles in The European Journal of Health Economics from Springer
Series data maintained by Sonal Shukla ().